帕金森病中睡眠上的黑素:一个随机的双盲安慰剂受控试验
Ramkumar Sugumaran1, Kadarla Shiva Sai Krishna1, Jayaram Saibaba1
1Department of Neurology, Jawaharlal Institute of Post Graduate Medical Education & Research (JIPMER), Puducherry, 605006, India.
Sleep medicine
|October 22, 2024
概括
黑色素显著改善了睡眠质量,并减少了白天的嗜睡在异常性帕金森症.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 睡眠障碍是异常帕金森病 (IPD) 中普遍存在的非运动性症状.
- 对于管理帕金森病患者睡眠问题的黑激素的疗效仍然不完全理解.
- 研究黑激素对IPD患者睡眠的影响对于改善患者生活质量至关重要.
研究的目的:
- 为了评估黑激素对异常帕金森病 (IPD) 患者睡眠的影响.
- 通过主观和客观的措施来评估睡眠质量和白天的嗜睡.
- 探索黑激素对多睡眠学参数,生活质量和运动/非运动症状的影响.
主要方法:
- 一项随机,双盲,安慰剂对照试验从2023年8月到2024年2月进行.
- 八十六名IPD患者被随机分配,接受3毫克的黑激素 (n=43) 或安慰剂 (n=43) 8周.
- 主要终点包括睡眠质量 (匹兹堡睡眠质量指数) 和白天嗜睡 (爱普沃思嗜睡量表),次要终点包括多睡眠学,生活质量和症状评估在基线和8周.
主要成果:
- 与安慰剂相比,黑色素治疗导致匹兹堡睡眠质量指数和爱普沃思睡眠度量得分在统计学上显著改善.
- 在非运动症状量表,帕金森病问卷 (PDQ-39) 和多睡眠学参数 (减少睡眠延迟,增加总睡眠时间) 中观察到有利于黑素的显著益处.
- 在使用黑色素时,报告的副作用很少.
结论:
- 黑色素证明了作为帕金森病患者睡眠障碍治疗选择的有效性和安全性.
- 睡眠质量的改善与增强的非运动症状和生活质量相关.
- 需要进一步的研究来确认这些发现在更广泛的帕金森病患者群体中的临床意义,考虑到年龄,疾病持续时间和药物使用等因素.
相关概念视频
01:19Management of Insomnia
234
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
234
01:24Parkinson's Disease: Treatment
227
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
227
01:15REM Sleep Behavior Disorder
154
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
154
01:15Parkinson's Disease: Overview
486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
149
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
149
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K